The mechanisms by which polyamines accelerate tumor spread

Journal of Experimental and Clinical Cancer Research

Volumn 30, Issue 1, 2011, Pages

  Soda, Kuniyasu ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

LAK; LFA 1; metastasis; Polyamine; spermidine; spermine

Indexed keywords

CATHEPSIN; CD18 ANTIGEN; CD56 ANTIGEN; EFLORNITHINE; HERMES ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MATRILYSIN; MEPRIN; MITOGUAZONE; PLASMINOGEN ACTIVATOR; POLYAMINE; SERINE PROTEINASE; SPERMIDINE; SPERMINE; UVOMORULIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD LEVEL; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER PATIENT; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CELL ADHESION; CELL LEVEL; CELL MEDIATED CYTOTOXICITY; CELL MOTILITY; CELL PROLIFERATION; COLON MUCOSA; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME SYNTHESIS; ERADICATION THERAPY; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMAN; HYPOXIA; IMMUNE DEFICIENCY; IMMUNODETECTION; INTESTINE ABSORPTION; LYMPHOKINE ACTIVATED KILLER CELL; METASTASIS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYAMINE SYNTHESIS; PRIORITY JOURNAL; PROGNOSIS; TUMOR ESCAPE; TUMOR VASCULARIZATION; UPREGULATION; URINE LEVEL; METABOLISM; NEOPLASM; PATHOLOGY; REVIEW;

HUMANS; NEOPLASMS; POLYAMINES;

EID: 80053643585     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-30-95     Document Type: Article

References (121)

1. Polyamines as markers of response and disease activity in cancer chemotherapy. Durie BG, Salmon SE, Russell DH, Cancer Res 1977 37 214 221 830407 (Pubitemid 8009300)
2. Polyamines in colorectal cancer. Evaluation of polyamine concentrations in the colon tissue, serum, and urine of 50 patients with colorectal cancer. Loser C, Folsch UR, Paprotny C, Creutzfeldt W, Cancer 1990 65 958 966 10.1002/1097-0142(19900215)65:4<958::AID-CNCR2820650423>3.0.CO;2-Z 2297664 (Pubitemid 20063503)
3. Red blood cell polyamines as biochemical markers of supratentorial malignant gliomas. Chatel M, Darcel F, Quemener V, Hercouet H, Moulinoux JP, Anticancer Res 1987 7 33 38 3566181
4. Urinary polyamines as a tumor marker. Kubota S, Okada M, Yoshimoto M, Murata N, Yamasaki Z, Wada T, Imahori K, Ohsawa N, Takaku F, Cancer Detect Prev 1985 8 189 192 4064039
5. Elevated contents of spermidine and spermine in the erythrocytes of cancer patients. Uehara N, Shirakawa S, Uchino H, Saeki Y, Cancer 1980 45 108 111 10.1002/1097-0142(19800101)45:1<108::AID-CNCR2820450120>3.0.CO;2-W 7350997 (Pubitemid 10214964)
6. Erythrocyte polyamines and prognosis in stage D2 prostatic carcinoma patients. Cipolla B, Guille F, Moulinoux JP, Bansard JY, Roth S, Staerman F, Corbel L, Quemener V, Lobel B, J Urol 1994 151 629 633 7508520 (Pubitemid 24054698)
7. Polyamine levels of human colorectal adenocarcinomas are correlated with tumor stage and grade. Weiss TS, Bernhardt G, Buschauer A, Thasler WE, Dolgner D, Zirngibl H, Jauch KW, Int J Colorectal Dis 2002 17 381 387 10.1007/s00384-002-0394-7 12355213 (Pubitemid 36075786)
8. Prognostic value of tissue polyamine levels in human colorectal carcinoma. Linsalata M, Caruso MG, Leo S, Guerra V, D'Attoma B, Di Leo A, Anticancer Res 2002 22 2465 2469 12174945 (Pubitemid 34857084)
9. Erythrocyte spermine levels: a prognostic parameter in childhood common acute lymphoblastic leukemia. Bergeron C, Bansard JY, Le Moine P, Bouet F, Goasguen JE, Moulinoux JP, Le Gall E, Catros-Quemener V, Leukemia 1997 11 31 36 10.1038/sj.leu.2400531 9001415 (Pubitemid 27065046)
10. Clinical relevance of polyamines. Russell DH, Crit Rev Clin Lab Sci 1983 18 261 311 6339165
11. Polyamines and protein kinase II. Effect of polyamines on cyclic AMP - dependent protein kinase from rat liver. Hochman J, Katz A, Bachrach U, Life Sci 1978 22 1481 1484 10.1016/0024-3205(78)90002-4 209271 (Pubitemid 8357588)
12. Activation of the proto-oncogene c-myc and c-fos by c-ras: involvement of polyamines. Tabib A, Bachrach U, Biochem Biophys Res Commun 1994 202 720 727 10.1006/bbrc.1994.1990 8048943 (Pubitemid 24259274)
13. Polyamines alter sequence-specific DNA-protein interactions. Panagiotidis CA, Artandi S, Calame K, Silverstein SJ, Nucleic Acids Res 1995 23 1800 1809 10.1093/nar/23.10.1800 7784186
14. Polyamine-dependent gene expression. Childs AC, Mehta DJ, Gerner EW, Cell Mol Life Sci 2003 60 1394 1406 10.1007/s00018-003-2332-4 12943227 (Pubitemid 36900522)
15. Polyamine oxidase, properties and functions. Seiler N, Prog Brain Res 1995 106 333 344 8584670 (Pubitemid 26027010)
16. Polyamine catabolism and disease. Casero RA, Pegg AE, Biochem J 2009 421 323 338 10.1042/BJ20090598 19589128
17. Mammalian polyamine metabolism and function. Pegg AE, IUBMB Life 2009 61 880 894 10.1002/iub.230 19603518
18. Polyamines and cancer: old molecules, new understanding. Gerner EW, Meyskens FL Jr, Nat Rev Cancer 2004 4 781 792 10.1038/nrc1454 15510159 (Pubitemid 39331150)
19. APC-dependent changes in expression of genes influencing polyamine metabolism, and consequences for gastrointestinal carcinogenesis, in the Min mouse. Erdman SH, Ignatenko NA, Powell MB, Blohm-Mangone KA, Holubec H, Guillen-Rodriguez JM, Gerner EW, Carcinogenesis 1999 20 1709 1713 10.1093/carcin/20.9.1709 10469614 (Pubitemid 29410548)
20. Polyamine levels in healthy and tumor tissues of patients with colon adenocarcinoma. Becciolini A, Porciani S, Lanini A, Balzi M, Cionini L, Bandettini L, Dis Colon Rectum 1991 34 167 173 10.1007/BF02049993 1993414
21. Prognostic value of ornithine decarboxylase and polyamines in human breast cancer: correlation with clinicopathologic parameters. Canizares F, Salinas J, de las Heras M, Diaz J, Tovar I, Martinez P, Penafiel R, Clin Cancer Res 1999 5 2035 2041 10473083 (Pubitemid 29399255)
22. Two chromosomal locations for human ornithine decarboxylase gene sequences and elevated expression in colorectal neoplasia. Radford DM, Nakai H, Eddy RL, Haley LL, Byers MG, Henry WM, Lawrence DD, Porter CW, Shows TB, Cancer Res 1990 50 6146 6153 1976038 (Pubitemid 20323665)
23. Polyamines in colorectal cancer. Kingsnorth AN, Lumsden AB, Wallace HM, Br J Surg 1984 71 791 794 10.1002/bjs.1800711019 6487981 (Pubitemid 14041889)
24. High ornithine decarboxylase activity and polyamine levels in human colorectal neoplasia. LaMuraglia GM, Lacaine F, Malt RA, Ann Surg 1986 204 89 93 10.1097/00000658-198607000-00013 3729588 (Pubitemid 16053831)
25. Selective elevation of the N1-acetylspermidine level in human colorectal adenocarcinomas. Takenoshita S, Matsuzaki S, Nakano G, Kimura H, Hoshi H, Shoda H, Nakamura T, Cancer Res 1984 44 845 847 6692383 (Pubitemid 14184628)
26. Spermidine uptake by erythrocytes from normal and Lewis lung carcinoma (3LL) grafted mice: I. In vitro study. Moulinoux JP, Quemener V, Khan NA, Delcros JG, Havouis R, Anticancer Res 1989 9 1057 1062 2817786 (Pubitemid 19266355)
27. Rapid absorption of luminal polyamines in a rat small intestine ex vivo model. Uda K, Tsujikawa T, Fujiyama Y, Bamba T, J Gastroenterol Hepatol 2003 18 554 559 10.1046/j.1440-1746.2003.03020.x 12702048 (Pubitemid 36645290)
28. Luminal and basolateral polyamine uptake by rat small intestine stimulated to grow by Phaseolus vulgaris lectin phytohaemagglutinin in vivo. Bardocz S, Brown DS, Grant G, Pusztai A, Biochim Biophys Acta 1990 1034 46 52 2109637 (Pubitemid 20114798)
29. Polyamines in food - implications for growth and health. Bardocz S, Grant G, Brown DS, Ralph A, Pusztai A, J Nutr Biochem 1993 4 66 71 10.1016/0955-2863(93)90001-D (Pubitemid 23178319)
30. Long-term oral polyamine intake increases blood polyamine concentrations. Soda K, Kano Y, Sakuragi M, Takao K, Lefor A, Konishi F, J Nutr Sci Vitaminol (Tokyo) 2009 55 361 366 10.3177/jnsv.55.361
31. Polyamine-rich food decreases age-associated pathology and mortality in aged mice. Soda K, Dobashi Y, Kano Y, Tsujinaka S, Konishi F, Exp Gerontol 2009 44 727 732 10.1016/j.exger.2009.08.013 19735716
32. Effects of dietary polyamines and clofibrate on metabolism of polyamines in the rat. Brodal BP, Eliassen KA, Ronning H, Osmundsen H, J Nutr Biochem 1999 10 700 708 10.1016/S0955-2863(99)00058-3 15539269
33. The gastrointestinal tract as polyamine source for tumor growth. Sarhan S, Knodgen B, Seiler N, Anticancer Res 1989 9 215 223 2495754
34. Polyamine uptake by human colon carcinoma cell line CaCo-2. D'Agostino L, Pignata S, Daniele B, D'Adamo G, Ferraro C, Silvestro G, Tagliaferri P, Contegiacomo A, Gentile R, Tritto G, et al. Digestion 1990 46 Suppl 2 352 359 2262067 (Pubitemid 20298734)
35. Polyamine uptake by bovine adrenocortical cells. Feige JJ, Chambaz EM, Biochim Biophys Acta 1985 846 93 100 10.1016/0167-4889(85)90114-4 2990582 (Pubitemid 15012800)
36. Polyamine compartmentalization in various human disease states. Cooper KD, Shukla JB, Rennert OM, Clin Chim Acta 1978 82 1 7 618672 (Pubitemid 8243076)
37. Polyamine levels and gastrin receptors in colon cancers. Upp JR Jr, Saydjari R, Townsend CM Jr, Singh P, Barranco SC, Thompson JC, Ann Surg 1988 207 662 669 10.1097/00000658-198806000-00004 3389934
38. Ornithine decarboxylase and polyamines in colorectal neoplasia and mucosa. Hixson LJ, Garewal HS, McGee DL, Sloan D, Fennerty MB, Sampliner RE, Gerner EW, Cancer Epidemiol Biomarkers Prev 1993 2 369 374 8348060
39. Gastrointestinal luminal polyamines: cellular accumulation and enterohepatic circulation. Osborne DL, Seidel ER, Am J Physiol 1990 258 576 584 2333971
40. Fate of orally administered 15N-labeled polyamines in rats bearing solid tumors. Kobayashi M, Xu YJ, Samejima K, Goda H, Niitsu M, Takahashi M, Hashimoto Y, Biol Pharm Bull 2003 26 285 288 10.1248/bpb.26.285 12612433 (Pubitemid 39663610)
41. Spermine, a natural polyamine, suppresses LFA-1 expression on human lymphocyte. Soda K, Kano Y, Nakamura T, Kasono K, Kawakami M, Konishi F, J Immunol 2005 175 237 245 15972654 (Pubitemid 40884324)
42. Increased blood spermine levels decrease the cytotoxic activity of lymphokine-activated killer cells: a novel mechanism of cancer evasion. Kano Y, Soda K, Nakamura T, Saitoh M, Kawakami M, Konishi F, Cancer Immunol Immunother 2007 56 771 781 10.1007/s00262-006-0229-4 16972077 (Pubitemid 46723577)
43. Effect of alpha-difluoromethylornithine in lung metastases before and after surgery of primary adenocarcinoma tumors in mice. Klein S, Miret JJ, Algranati ID, de Lustig ES, Biol Cell 1985 53 33 36 3158365 (Pubitemid 15084253)
44. Effects of alpha-difluoromethylornithine and methylglyoxal bis(guanylhydrazone) on the growth of experimental renal adenocarcinoma in mice. Herr HW, Kleinert EL, Conti PS, Burchenal JH, Whitmore WF Jr, Cancer Res 1984 44 4382 4385 6432312 (Pubitemid 14018030)
45. Successful treatment with DL-alpha-difluoromethylornithine in established human small cell variant lung carcinoma implants in athymic mice. Luk GD, Abeloff MD, Griffin CA, Baylin SB, Cancer Res 1983 43 4239 4243 6409400 (Pubitemid 13044045)
46. Effects of alpha-difluoromethylornithine on the growth of experimental Wilms' tumor and renal adenocarcinoma. Kingsnorth AN, McCann PP, Diekema KA, Ross JS, Malt RA, Cancer Res 1983 43 4031 4034 6307502 (Pubitemid 13041024)
47. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. Prados MD, Wara WM, Sneed PK, McDermott M, Chang SM, Rabbitt J, Page M, Malec M, Davis RL, Gutin PH, et al. Int J Radiat Oncol Biol Phys 2001 49 71 77 10.1016/S0360-3016(00)01458-9 11163499 (Pubitemid 32041278)
48. Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer. Messing E, Kim KM, Sharkey F, Schultz M, Parnes H, Kim D, Saltzstein D, Wilding G, J Urol 2006 176 500 504 10.1016/j.juro.2006.03.061 16813878 (Pubitemid 43949406)
49. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Meyskens FL Jr, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, Kelloff G, Lawson MJ, Kidao J, McCracken J, et al. Cancer Prev Res (Phila) 2008 1 32 38 10.1158/1940-6207.CAPR-08-0042
50. Polyamine deprivation enhances antitumoral efficacy of chemotherapy. Quemener V, Moulinoux JP, Havouis R, Seiler N, Anticancer Res 1992 12 1447 1453 1444206
51. Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma. Thompson PA, Wertheim BC, Zell JA, Chen WP, McLaren CE, LaFleur BJ, Meyskens FL, Gerner EW, Gastroenterology 2010 139 797 805 805 e791 10.1053/j.gastro.2010.06.005 20538001
52. Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Levin VA, Hess KR, Choucair A, Flynn PJ, Jaeckle KA, Kyritsis AP, Yung WK, Prados MD, Bruner JM, Ictech S, et al. Clin Cancer Res 2003 9 981 990 12631596 (Pubitemid 36323701)
53. Effects of polyamine depletion by alpha-difluoromethylornithine on in vitro and in vivo biological properties of 4T1 murine mammary cancer cells. Jun JY, Griffith JW, Bruggeman R, Washington S, Demers LM, Verderame MF, Manni A, Breast Cancer Res Treat 2008 107 33 40 17333337 (Pubitemid 350179593)
54. Effects of DL-alpha-difluoromethylornithine on the growth and metastasis of B16 melanoma in vivo. Kubota S, Ohsawa N, Takaku F, Int J Cancer 1987 39 244 247 10.1002/ijc.2910390220 3100460 (Pubitemid 17015287)
55. Effects of polyamine synthesis inhibitors on primary tumor features and metastatic capacity of human breast cancer cells. Manni A, Washington S, Hu X, Griffith JW, Bruggeman R, Demers LM, Mauger D, Verderame MF, Clin Exp Metastasis 2005 22 255 263 10.1007/s10585-005-8480-1 16158253 (Pubitemid 41298007)
56. Molecular basis of tumour metastasis. MacDonald NJ, Steeg PS, Cancer Surv 1993 16 175 199 7688661 (Pubitemid 23268918)
57. Tumor invasion and the extracellular matrix. Liotta LA, Rao CN, Barsky SH, Lab Invest 1983 49 636 649 6317982 (Pubitemid 14220329)
58. Epithelial-mesenchymal transition: a cancer researcher's conceptual friend and foe. Klymkowsky MW, Savagner P, Am J Pathol 2009 174 1588 1593 10.2353/ajpath.2009.080545 19342369
59. Hypoxia signalling in cancer and approaches to enforce tumour regression. Pouyssegur J, Dayan F, Mazure NM, Nature 2006 441 437 443 10.1038/nature04871 16724055 (Pubitemid 44050138)
60. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. Hockel M, Vaupel P, J Natl Cancer Inst 2001 93 266 276 10.1093/jnci/93.4.266 11181773 (Pubitemid 32219813)
61. Hypoxia - a key regulatory factor in tumour growth. Harris AL, Nat Rev Cancer 2002 2 38 47 10.1038/nrc704 11902584 (Pubitemid 37328806)
62. Regulation of E-cadherin: does hypoxia initiate the metastatic cascade? Beavon IR, Mol Pathol 1999 52 179 188 10.1136/mp.52.4.179 10694937 (Pubitemid 29369202)
63. Hypoxia facilitates tumour cell detachment by reducing expression of surface adhesion molecules and adhesion to extracellular matrices without loss of cell viability. Hasan NM, Adams GE, Joiner MC, Marshall JF, Hart IR, Br J Cancer 1998 77 1799 1805 10.1038/bjc.1998.299 9667649 (Pubitemid 28254614)
64. Involvement of polyamines in apoptosis of cardiac myoblasts in a model of simulated ischemia. Tantini B, Fiumana E, Cetrullo S, Pignatti C, Bonavita F, Shantz LM, Giordano E, Muscari C, Flamigni F, Guarnieri C, et al. J Mol Cell Cardiol 2006 40 775 782 10.1016/j.yjmcc.2006.03.002 16678846 (Pubitemid 43817037)
65. Multiple polyamine transport pathways in cultured pulmonary artery smooth muscle cells: regulation by hypoxia. Aziz SM, Olson JW, Gillespie MN, Am J Respir Cell Mol Biol 1994 10 160 166 8110472
66. Spermine accelerates hypoxia-initiated cancer cell migration. Tsujinaka S, Soda K, Kano Y, Konishi F, Int J Oncol 2011 38 305 312 21132262
67. CD44 and CD44v6 downregulation in clinical prostatic carcinoma: relation to Gleason grade and cytoarchitecture. De Marzo AM, Bradshaw C, Sauvageot J, Epstein JI, Miller GJ, Prostate 1998 34 162 168 10.1002/(SICI)1097- 0045(19980215)34:3<162::AID-PROS2>3.0.CO;2-K 9492843 (Pubitemid 28156605)
68. Decreased levels of CD44 protein and mRNA in prostate carcinoma. Correlation with tumor grade and ploidy. Kallakury BV, Yang F, Figge J, Smith KE, Kausik SJ, Tacy NJ, Fisher HA, Kaufman R, Figge H, Ross JS, Cancer 1996 78 1461 1469 10.1002/(SICI)1097-0142(19961001)78:7<1461::AID-CNCR13>3.0.CO;2- Y 8839552 (Pubitemid 26317867)
69. Antimetastatic activity of DL-alpha-difluoromethylornithine, an inhibitor of polyamine biosynthesis, in mice. Sunkara PS, Rosenberger AL, Cancer Res 1987 47 933 935 3100031 (Pubitemid 17027904)
70. Matrix metalloproteinases as stromal effectors of human carcinoma progression: therapeutic implications. Basset P, Okada A, Chenard MP, Kannan R, Stoll I, Anglard P, Bellocq JP, Rio MC, Matrix Biol 1997 15 535 541 10.1016/S0945-053X(97)90028-7 9138286 (Pubitemid 27190028)
71. Matrix metalloproteinases: biologic activity and clinical implications. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM, J Clin Oncol 2000 18 1135 1149 10694567 (Pubitemid 30123793)
72. Matrix metalloproteinases: regulators of the tumor microenvironment. Kessenbrock K, Plaks V, Werb Z, Cell 2010 141 52 67 10.1016/j.cell.2010.03.015 20371345
73. Tumor microenvironment and progression. Dvorak HF, Weaver VM, Tlsty TD, Bergers G, J Surg Oncol 2011 103 468 474 10.1002/jso.21709 21480238
74. Ornithine decarboxylase overexpression in mouse 10T1/2 fibroblasts: cellular transformation and invasion. Kubota S, Kiyosawa H, Nomura Y, Yamada T, Seyama Y, J Natl Cancer Inst 1997 89 567 571 10.1093/jnci/89.8.567 9106645 (Pubitemid 27172946)
75. Putrescine-dependent invasive capacity of rat ascites hepatoma cells. Ashida Y, Kido J, Kinoshita F, Nishino M, Shinkai K, Akedo H, Inoue H, Cancer Res 1992 52 5313 5316 1394136
76. Polyamine-dependent expression of the matrix metalloproteinase matrilysin in a human colon cancer-derived cell line. Wallon UM, Shassetz LR, Cress AE, Bowden GT, Gerner EW, Mol Carcinog 1994 11 138 144 10.1002/mc.2940110304 7945802 (Pubitemid 24372805)
77. Inhibitors of polyamine biosynthesis decrease the expression of the metalloproteases meprin alpha and MMP-7 in hormone-independent human breast cancer cells. Matters GL, Manni A, Bond JS, Clin Exp Metastasis 2005 22 331 339 10.1007/s10585-005-0660-5 16170669 (Pubitemid 41374289)
78. Human ornithine decarboxylase-overproducing NIH3T3 cells induce rapidly growing, highly vascularized tumors in nude mice. Auvinen M, Laine A, Paasinen-Sohns A, Kangas A, Kangas L, Saksela O, Andersson LC, Holtta E, Cancer Res 1997 57 3016 3025 9230217 (Pubitemid 27315055)
79. Tumor angiogenesis and polyamines: alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits B16 melanoma-induced angiogenesis in ovo and the proliferation of vascular endothelial cells in vitro. Takigawa M, Enomoto M, Nishida Y, Pan HO, Kinoshita A, Suzuki F, Cancer Res 1990 50 4131 4138 1693880 (Pubitemid 20225641)
80. Deficient strongly adherent monocytes in the peripheral blood of cancer patients. Hersh EM, Gschwind C, Morris DL, Murphy S, Cancer Immunol Immunother 1982 14 105 109 6965225 (Pubitemid 13174978)
81. Tube leukocyte adherence inhibition assay for the detection of anti-tumor immunity. I. Monocyte is the reactive cell. Grosser N, Marti JH, Proctor JW, Thomson DM, Int J Cancer 1976 18 39 47 10.1002/ijc.2910180107 1084863
82. Predictive value of tube leukocyte adherence inhibition (LAI) assay for breast, colorectal, stomach and pancreatic cancer. MacFarlane JK, Thomson DM, Phelan K, Shenouda G, Scanzano R, Cancer 1982 49 1185 1193 10.1002/1097- 0142(19820315)49:6<1185::AID-CNCR2820490620>3.0.CO;2-E 7037158 (Pubitemid 12187821)
83. Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection. Heriot AG, Marriott JB, Cookson S, Kumar D, Dalgleish AG, Br J Cancer 2000 82 1009 1012 10.1054/bjoc.1999.1034 10737381 (Pubitemid 30128851)
84. Immunological variations in women suffering from ovarian cancer. Influence of radical surgical treatment. Rampone B, Rampone A, Tirabasso S, Panariello S, Rampone N, Minerva Ginecol 2001 53 116 119 11526704 (Pubitemid 33632069)
85. Decreased interleukin-2 production in patients with gastrointestinal cancer. Monson JR, Ramsden C, Guillou PJ, Br J Surg 1986 73 483 486 10.1002/bjs.1800730620 3487366 (Pubitemid 16092851)
86. Depressed lymphokine activated killer cell activity in mycosis fungoides. A possible marker for aggressive disease. Wood NL, Kitces EN, Blaylock WK, Arch Dermatol 1990 126 907 913 10.1001/archderm.126.7.907 2360838 (Pubitemid 20224547)
87. Reduced LAK cytotoxicity of peripheral blood mononuclear cells in patients with bladder cancer: decreased LAK cytotoxicity caused by a low incidence of CD56+ and CD57+ mononuclear blood cells. Hermann GG, Petersen KR, Steven K, Zeuthen J, J Clin Immunol 1990 10 311 320 10.1007/BF00917476 1707414
88. Natural killer (NK) and lymphokine-activated killer (LAK) cell functions from healthy dogs and 29 dogs with a variety of spontaneous neoplasms. Funk J, Schmitz G, Failing K, Burkhardt E, Cancer Immunol Immunother 2005 54 87 92 10.1007/s00262-004-0555-3 15693143 (Pubitemid 40064489)
89. Cellular immune defects in patients with melanoma involving interleukin-2-activated lymphocyte cytotoxicity and a serum suppressor factor. Balch CM, Itoh K, Tilden AB, Surgery 1985 98 151 157 3875156 (Pubitemid 16161446)
90. Inhibition of interleukin 2 production by factors released from tumor cells. Hersey P, Bindon C, Czerniecki M, Spurling A, Wass J, McCarthy WH, J Immunol 1983 131 2837 2842 6605993 (Pubitemid 14208130)
91. Modulation of TcR/CD3-zeta chain expression by a circulating factor derived from ovarian cancer patients. Taylor DD, Bender DP, Gercel-Taylor C, Stanson J, Whiteside TL, Br J Cancer 2001 84 1624 1629 10.1054/bjoc.2001.1847 11401315 (Pubitemid 32612493)
92. Synthetic polyamines added to cultures containing bovine sera reversibly inhibit in vitro parameters of immunity. Byrd WJ, Jacobs DM, Amoss MS, Nature 1977 267 621 623 10.1038/267621a0 141619
93. Polyamine deprivation prevents the development of tumour-induced immune suppression. Chamaillard L, Catros-Quemener V, Delcros JG, Bansard JY, Havouis R, Desury D, Commeurec A, Genetet N, Moulinoux JP, Br J Cancer 1997 76 365 370 10.1038/bjc.1997.391 9252204 (Pubitemid 27308087)
94. Highly oncolytic adherent lymphocytes: therapeutic relevance for leukemia. Lotzova E, Savary CA, Totpal K, Schachner J, Lichtiger B, McCredie KB, Freireich EJ, Leuk Res 1991 15 245 254 10.1016/0145-2126(91)90127-F 2030606
95. Polyamine concentrations in pancreatic tissue, serum, and urine of patients with pancreatic cancer. Loser C, Folsch UR, Paprotny C, Creutzfeldt W, Pancreas 1990 5 119 127 10.1097/00006676-199003000-00001 2315288 (Pubitemid 20074052)
96. Erythrocyte-binding polyamine as a tumor growth marker for human hepatocellular carcinoma. Nishiguchi S, Tamori A, Koh N, Fujimoto S, Takeda T, Shiomi S, Oka H, Yano Y, Otani S, Kuroki T, Hepatogastroenterology 2002 49 504 507 11995483 (Pubitemid 34606583)
97. Serum polyamine alterations in surgical patients with colorectal carcinoma. Nishioka K, Romsdahl MM, McMurtrey MJ, J Surg Oncol 1977 9 555 562 10.1002/jso.2930090605 592854 (Pubitemid 8257678)
98. Transport and metabolism of polyamines in human lymphocytes. Colombatto S, Fasulo L, Fulgosi B, Grillo MA, Int J Biochem 1990 22 489 492 10.1016/0020-711X(90)90262-2 2161357 (Pubitemid 20238347)
99. Polyamine metabolism and uptake during Phaseolus vulgaris lectin, PHA-induced growth of rat small intestine. Bardocz S, Grant G, Brown DS, Ewen SW, Nevison I, Pusztai A, Digestion 1990 46 Suppl 2 360 366 2262068 (Pubitemid 20298735)
100. Distribution of spermidine and spermine in blood from cystic fibrosis patients and control subjects. Cohen LF, Lundgren DW, Farrell PM, Blood 1976 48 469 475 953366
101. Functional heterogeneity of Leu 19"bright"+ and Leu 19"dim"+ lymphokine-activated killer cells. Ellis TM, Fisher RI, J Immunol 1989 142 2949 2954 2467946 (Pubitemid 19114919)
102. Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens. Weil-Hillman G, Fisch P, Prieve AF, Sosman JA, Hank JA, Sondel PM, Cancer Res 1989 49 3680 3688 2471587 (Pubitemid 19178196)
103. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Mule JJ, Shu S, Schwarz SL, Rosenberg SA, Science 1984 225 1487 1489 10.1126/science.6332379 6332379 (Pubitemid 14033135)
104. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. Rosenberg SA, Mule JJ, Spiess PJ, Reichert CM, Schwarz SL, J Exp Med 1985 161 1169 1188 10.1084/jem.161.5.1169 3886826 (Pubitemid 15011332)
105. Spermine and spermidine induce some of the immune suppression observed in cancer patients. Soda K, Kano Y, Nakamura T, Kawakami M, Konishi F, Annals of Cancer Research and Therapy 2003 11 243 253 (Pubitemid 39334898)
106. Spermine inhibits proinflammatory cytokine synthesis in human mononuclear cells: a counterregulatory mechanism that restrains the immune response. Zhang M, Caragine T, Wang H, Cohen PS, Botchkina G, Soda K, Bianchi M, Ulrich P, Cerami A, Sherry B, Tracey KJ, J Exp Med 1997 185 1759 1768 10.1084/jem.185.10. 1759 9151701 (Pubitemid 27242197)
107. Spermine differentially regulates the production of interleukin-12 p40 and interleukin-10 and suppresses the release of the T helper 1 cytokine interferon-gamma. Hasko G, Kuhel DG, Marton A, Nemeth ZH, Deitch EA, Szabo C, Shock 2000 14 144 149 10.1097/00024382-200014020-00012 10947158
108. The effect of alpha-difluoromethylornithine, an inhibitor of polyamine biosynthesis, on mitogen-induced interleukin 2 production. Bowlin TL, McKown BJ, Sunkara PS, Immunopharmacology 1987 13 143 147 10.1016/0162-3109(87)90051-8 3110101 (Pubitemid 17052437)
109. Polyamine deprivation stimulates natural killer cell activity in cancerous mice. Chamaillard L, Quemener V, Havouis R, Moulinoux JP, Anticancer Res 1993 13 1027 1033 8352521 (Pubitemid 23247457)
110. An endotoxin-induced serum factor that causes necrosis of tumors. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B, Proc Natl Acad Sci USA 1975 72 3666 3670 10.1073/pnas.72.9.3666 1103152
111. Leukocyte function-associated antigen 1 is an activation molecule for human T cells. Wacholtz MC, Patel SS, Lipsky PE, J Exp Med 1989 170 431 448 10.1084/jem.170.2.431 2569026 (Pubitemid 19204273)
112. The LFA-1/ICAM cell adhesion pathway is involved in tumor-cell lysis mediated by bispecific monoclonal-antibody-targeted T lymphocytes. Ferrini S, Sforzini S, Cambiaggi A, Poggi A, Meazza R, Canevari S, Colnaghi MI, Moretta L, Int J Cancer 1994 56 846 852 10.1002/ijc.2910560616 7907079 (Pubitemid 24102752)
113. Effect of polyamine deprivation on the survival of intracranial glioblastoma bearing rats. Sarhan S, Weibel M, Seiler N, Anticancer Res 1991 11 987 992 2064355
114. Endogenous and exogenous polyamines in support of tumor growth. Seiler N, Sarhan S, Grauffel C, Jones R, Knodgen B, Moulinoux JP, Cancer Res 1990 50 5077 5083 2116224 (Pubitemid 20257939)
115. Polyamine reduced diet (PRD) nutrition therapy in hormone refractory prostate cancer patients. Cipolla BG, Havouis R, Moulinoux JP, Biomed Pharmacother 2010 64 363 368 10.1016/j.biopha.2009.09.022 20106631
116. The role of LGL/NK cells in surgery-induced promotion of metastasis and its attenuation by morphine. Page GG, Ben-Eliyahu S, Liebeskind JC, Brain Behav Immun 1994 8 241 250 10.1006/brbi.1994.1022 7865895 (Pubitemid 24344872)
117. Surgical stress-mediated suppression of murine natural killer cell cytotoxicity. Pollock RE, Babcock GF, Romsdahl MM, Nishioka K, Cancer Res 1984 44 3888 3891 6744305 (Pubitemid 14041610)
118. Enhancing effect of thoracotomy and/or laparotomy on the development of the lung metastases in rats after intravenous inoculation of tumor cells. Hattori T, Hamai Y, Harada T, Ikeda H, Ikeda T, Jpn J Surg 1977 7 263 268 10.1007/BF02469360 606897 (Pubitemid 8276523)
119. Human erythrocyte polyamine levels after partial hepatectomy. Tsukamoto T, Kinoshita H, Hirohashi K, Kubo S, Otani S, Hepatogastroenterology 1997 44 744 750 9222683 (Pubitemid 27281111)
120. The potential of a novel polyamine transport inhibitor in cancer chemotherapy. Aziz SM, Gillespie MN, Crooks PA, Tofiq SF, Tsuboi CP, Olson JW, Gosland MP, J Pharmacol Exp Ther 1996 278 185 192 8764350 (Pubitemid 27167094)
121. Combination therapy with 2-difluoromethylornithine and a polyamine transport inhibitor against murine squamous cell carcinoma. Chen Y, Weeks RS, Burns MR, Boorman DW, Klein-Szanto A, O'Brien TG, Int J Cancer 2006 118 2344 2349 10.1002/ijc.21621 16331620